Savaysa

Quick links to important sections

Savaysa

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Savaysa

Quick Facts: Savaysa (Edoxaban)

Property Description
Active ingredient Edoxaban (as tosylate monohydrate)
Form Tablet (Oral)
Pharmacological class Direct Factor Xa Inhibitor
Common use Prevention of pathological blood clots
Origin Synthetic, small molecule

What Type of Medicine is Savaysa (Edoxaban)?

Savaysa is the United States trade name for the synthetic, prescription-only medication containing the active ingredient Edoxaban, which is classified as a modern anticoagulant or blood thinner. The medication is manufactured by Daiichi Sankyo and is administered orally as a film-coated tablet for adult patients. Edoxaban is classified as a Direct Oral Anticoagulant (DOAC), placing it among the newer generation of antithrombotic agents.

How Does Savaysa Fit the Anticoagulant Category?

The medicine’s therapeutic class is a Direct Factor Xa Inhibitor. This precise function involves the selective and direct inhibition of Factor Xa (FXa), an essential enzyme within the body’s coagulation cascade. By blocking FXa, Edoxaban effectively prevents the mass production of thrombin, the substance required to create the final stabilizing meshwork of a clot known as fibrin. This targeted action provides a predictable means of controlling the blood's ability to coagulate, distinguishing it from older anticoagulant classes.

What is the General Purpose of Taking Savaysa?

The core role of Edoxaban is to provide antithrombotic protection by consistently reducing the risk of unwanted or pathological blood clot formation within the circulatory system. The fundamental benefit is to maintain clear and unobstructed blood flow, thereby minimizing the potential for serious health consequences that arise when clots obstruct blood vessels in vital organs. In contrast to older drug classes, Edoxaban offers the practical benefit of simplified patient management.

Regulatory References

  1. NIH StatPearls: Edoxaban

What side effects are possible with Savaysa?

Possible Side Effects and Safety Information

Savaysa (edoxaban) is an anticoagulant medication that carries a significant risk of bleeding, which can be serious and potentially fatal. All forms of bleeding are possible, including major, clinically relevant non-major, and critical organ bleeding such as intracranial hemorrhage (ICH).

Key Safety Concerns and Warnings

Official regulatory documents include three Boxed Warnings detailing critical safety issues:

  • Reduced Efficacy in NVAF with High Kidney Function: Savaysa should not be used in patients with nonvalvular atrial fibrillation (NVAF) who have a creatinine clearance (CrCL) greater than 95 mL/min. In this specific population, the drug has shown reduced efficacy compared to warfarin, resulting in an increased risk of ischemic stroke.
  • Increased Ischemic Risk Upon Discontinuation: Premature discontinuation of Savaysa in NVAF patients increases the risk of stroke. If the medication is stopped for reasons other than bleeding or completion of therapy, coverage with another anticoagulant is required.
  • Spinal/Epidural Hematoma: Patients receiving neuraxial anesthesia (e.g., epidural) or undergoing spinal puncture are at risk of developing spinal or epidural hematomas, which may lead to long-term or permanent paralysis. This risk is increased by concomitant use of other drugs affecting blood clotting.

Common and Other Adverse Reactions

Common adverse reactions reported in clinical trials include bleeding (e.g., gastrointestinal bleeding, epistaxis), anemia (low red blood cell count), rash, and abnormal liver function tests. Uncommon or rare reactions documented include hypersensitivity, urticaria, and anaphylactic reactions.

Contraindications and Restrictions

Savaysa is contraindicated in patients with active pathological bleeding. Its use is not recommended in patients with mechanical heart valves, moderate to severe mitral stenosis, or moderate or severe hepatic impairment. Due to bleeding risk, the drug is typically held for at least 24 hours prior to invasive or surgical procedures.

Overdose and Emergency Response

Overdose and when to seek help

Savaysa (edoxaban) is a Direct Factor Xa inhibitor, and official regulatory labeling indicates that the primary manifestation of overdose or overexposure is a significantly increased risk of bleeding and hemorrhage. This serious outcome stems from an exaggeration of the drug’s anticoagulant effect. Documented signs of severe overexposure include external or internal bleeding such as bloody, black, or tarry stools, vomiting blood or coffee-ground material, and blood in the urine (macroscopic hematuria). Systemic signs of blood loss like dizziness or anemia may also present.

Overdose with edoxaban is classified as potentially life-threatening due to the risk of serious and potentially fatal bleeding. Regulatory authorities mandate that individuals experiencing uncontrolled or severe bleeding must seek immediate medical attention and contact emergency services or Poison Control. It is required to promptly evaluate any signs or symptoms of blood loss.

The official prescribing information confirms that no specific antidote is available to reverse edoxaban’s anticoagulant effects. Furthermore, agents such as protamine sulfate or vitamin K are not expected to be effective. Management should therefore consist of general symptomatic and supportive treatment. Hemodialysis is not effective for drug clearance.

Therapeutic Uses of Savaysa

What Savaysa Treats: Main Uses and Benefits

Savaysa (edoxaban) is a medication generally used to manage and prevent the serious health problems associated with blood clots. Its primary applications include managing the risk of stroke in people with non-valvular atrial fibrillation (AFib), and treating and addressing the recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Preventing Stroke for Atrial Fibrillation

For individuals with AFib, this treatment may assist with maintaining functional stability and supports the patient during difficult episodes by easing distress related to stroke risk. This medicine is generally used to help manage the risk of stroke in people with non-valvular atrial fibrillation.


Treating and Preventing Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

When used for DVT or PE, Savaysa is commonly used to help provide symptomatic assistance by addressing symptoms related to the existing clot. It may assist in easing the symptomatic burden associated with physical discomfort, such as pain, swelling, or shortness of breath. In the long-term, it may be part of symptomatic management by addressing the recurrence of conditions involving heightened physiological activity.

Quick Fact: Relevant for Systemic Conditions This medicine is relevant for managing symptoms related to systemic imbalance and heightened physiological activity that could interfere with daily functioning.

Eligibility and Restrictions for Use

Who Can and Cannot Use Savaysa? (Edoxaban)

The eligibility for using Savaysa is strictly defined by regulatory authorities based on specific patient populations and existing medical conditions. Use is generally permitted for adult patients (≥ 18 years of age) with specific conditions like non-valvular atrial fibrillation (NVAF), deep vein thrombosis (DVT), or pulmonary embolism (PE), provided they meet specific criteria.


Contraindications and Restrictions

Savaysa is contraindicated in several populations. Patients must not use this medicine if they have active pathological bleeding or a known hypersensitivity to edoxaban. The medicine is also prohibited for patients with mechanical prosthetic heart valves or moderate-to-severe mitral stenosis. Individuals with uncontrolled severe hypertension or severe hepatic disease associated with a bleeding risk are also excluded from use.


Population-Specific Limitations

Specific limitations exist based on organ function and age:

  • Renal Function: For NVAF, the medicine is not recommended for patients with very high renal function (Creatinine Clearance (CrCl) > 95 mL/min) due to reduced efficacy. Use is also restricted for those with severe impairment.
  • Pediatric Use: Safety and efficacy have not been established in the pediatric population (under 18 years), and use is not recommended.
  • Pregnancy and Lactation: Use is not recommended or contraindicated during pregnancy or while breastfeeding due to potential hemorrhage risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Savaysa (edoxaban) is primarily structured around its relationship with the P-glycoprotein (P-gp) transporter and its effects on hemostasis (blood clotting). The official regulatory documentation outlines specific constraints for co-administration with other medicines, based on their effect on P-gp activity or bleeding risk.

Pharmacokinetic Interactions (P-gp Modulation)

  • P-gp Inhibitors: Co-administration with certain P-gp inhibitors, such as Amiodarone, Dronedarone, Erythromycin, or Ketoconazole, increases Savaysa plasma concentrations. For patients being treated for Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), a dose reduction is required when taken with these specific inhibitors. However, this dose adjustment is not recommended for patients with Nonvalvular Atrial Fibrillation (NVAF).
  • P-gp Inducers: Concomitant use with the potent P-gp inducer Rifampin is contraindicated (avoided) as it significantly decreases Savaysa exposure, potentially reducing its effect.

Pharmacodynamic Interactions (Bleeding Risk)

  • Co-administration with other agents that interfere with blood clotting is a major concern due to an increased risk of bleeding. Medicines that require caution and close monitoring when used with Savaysa include other anticoagulants, antiplatelet agents (such as Aspirin and Clopidogrel), and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
  • Long-term use of Savaysa with other oral anticoagulants is generally not recommended.

Mechanism of Action

Direct Blockade of Factor Xa (FXa)

Edoxaban acts by disrupting the final common pathway of the body's coagulation cascade. Its action is focused on two primary mechanistic domains that modulate the final steps of coagulation. Edoxaban functions as a direct, selective, and reversible inhibitor of Factor Xa (FXa), a critical enzyme at the convergence point of the clotting cascade. By binding to the active site of FXa, the drug prevents the enzyme from assembling the Prothrombinase Complex. This molecular blockade suppresses the subsequent steps of the coagulation process.

Suppression of Thrombin and Fibrin Generation

The inhibition of FXa profoundly reduces the conversion of Prothrombin into Thrombin (Factor IIa). Since Thrombin is essential for cleaving Fibrinogen into the structural Fibrin meshwork, the suppression of Thrombin generation limits the formation of a stable fibrin meshwork. This molecular cascade results in the systemic modulation of coagulation.

Dosage and Administration Information

How Savaysa (Edoxaban) is Used: Official Administration Guidelines

Savaysa is an anticoagulant medication administered according to specific established protocols. These instructions address the route, frequency, dosing adjustments, and procedural steps for its proper use.


Official Dosing and Administration

Parameter Description
Route of Administration The medication is taken orally as a film-coated tablet.
Standard Dosing The typical recommended adult dose is 60 mg taken once daily.
Timing and Frequency Savaysa is taken once daily and can be administered with or without food.
Missed Dose Rule If a dose is missed, it should be taken immediately on the same day and the regular schedule resumed the next day. The dose should not be doubled.
Preparation Tablets may be crushed and mixed with water or soft food (like applesauce) for immediate use, including administration via a gastric tube.

Required Dose Adjustments

Specific patient profiles require a reduced dose of 30 mg once daily, determined by pre-treatment assessment. This adjustment applies to patients with:

  • Impaired Kidney Function: Individuals with a creatinine clearance (CrCL) between 15 and 50 mL/min.
  • Low Body Weight: Patients weighing 60 kg or less.
  • Concomitant Use: Patients taking specific P-glycoprotein (P-gp) inhibitors, such as cyclosporine, dronedarone, erythromycin, or ketoconazole.

Use for Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

For the treatment of DVT and PE, the administration of Savaysa is sequential. It must be started after the completion of 5 to 10 days of initial therapy with an injectable (parenteral) anticoagulant. Before treatment begins, kidney function must be assessed to select the correct dosing regimen.

Recent Clinical Evidence

The Foundation of Edoxaban (Savaysa) Research

Clinical evidence supporting the use of edoxaban (Savaysa) is primarily derived from two large-scale, international Phase III trials: ENGAGE AF-TIMI 48 for nonvalvular atrial fibrillation (NVAF) and Hokusai-VTE for venous thromboembolism (VTE).


Efficacy and Safety in Atrial Fibrillation (NVAF)

The ENGAGE AF-TIMI 48 trial compared edoxaban against dose-adjusted warfarin in over 21,000 NVAF patients. The results showed that edoxaban was non-inferior to warfarin for the primary efficacy endpoint of preventing stroke or systemic embolic events (SEE).

Regarding the primary safety endpoint, the trial demonstrated that edoxaban was associated with significantly lower rates of major bleeding, including intracranial hemorrhage, compared to warfarin. This reduction in major bleeding was observed across both the higher and lower dose regimens studied.

Important Context: A key finding from this study was the observation that the 60 mg edoxaban regimen was associated with an increased rate of ischemic stroke compared to warfarin in a specific patient subgroup: those with very good kidney function (creatinine clearance, or CrCL, greater than 95 mL/min). Consequently, edoxaban is not recommended for stroke prevention in NVAF patients with CrCL > 95 mL/min.


Treatment of Venous Thromboembolism (VTE)

The Hokusai-VTE trial evaluated edoxaban following initial treatment with an injectable blood thinner for patients with deep vein thrombosis (DVT) or pulmonary embolism (PE). The study demonstrated that edoxaban was non-inferior to warfarin in preventing the recurrence of VTE events. Crucially, the edoxaban regimen was also associated with a significantly lower rate of clinically relevant non-major bleeding (CRNMB) and major bleeding compared to warfarin in this patient population, supporting its use as a continuous treatment following initial parenteral therapy.

Frequently Asked Questions (FAQ)

Common questions about Savaysa (FAQ)

Q: How is Savaysa different from other blood thinners people talk about?

Savaysa is categorized as a Direct Oral Anticoagulant (DOAC), and its mechanism involves directly inhibiting a clotting substance called Factor Xa. Official product information indicates that unlike some older blood thinners, Savaysa generally does not require routine blood tests to monitor the effect of the medication. This targeted action is a key difference between it and other anticoagulant classes.

Q: Why would someone switch from another anticoagulant to Savaysa?

Decisions regarding a medication switch are made by a healthcare provider based on a patient’s specific health needs. Clinical studies, such as the one comparing edoxaban to warfarin, demonstrated that edoxaban was associated with a significantly lower risk of major bleeding. Regulatory documents also provide clear guidance on the safe process for transitioning between different anticoagulant medicines.

Q: Does Savaysa need regular blood testing like some other medications?

According to official product information, routine blood tests to check how well the medicine is working are not generally required for Savaysa. This is a key distinction from some older anticoagulant medicines.

Q: How quickly does Savaysa start working after the first dose?

Edoxaban, the active ingredient, is designed to be rapidly absorbed by the body after the tablet is taken. Regulatory data on its pharmacology indicate that the drug reaches its peak concentration in the bloodstream within approximately one to two hours.

Q: Can I drink coffee or tea while taking Savaysa?

Official guidance states there are no specific restrictions regarding the consumption of beverages like coffee or tea while using Savaysa. Furthermore, the drug can be taken with or without food as part of its once-daily administration.

Q: Does alcohol consumption affect how Savaysa works?

Regulatory information indicates that moderate alcohol consumption does not typically pose a specific interaction risk with Savaysa. However, because Savaysa is a blood thinner, official information confirms that heavy drinking can significantly increase the risk of bleeding. This elevated risk is why heavy drinking is not advised while taking the medication.

Q: Is Savaysa safe for people with kidney problems?

Use of Savaysa is closely managed based on kidney function. Official regulatory information requires that the dose is adjusted (reduced) for patients with mildly or moderately impaired kidney function. The medicine is not recommended for patients with nonvalvular atrial fibrillation who have very high kidney function or those with severe kidney impairment.

Q: What are the concerns about using Savaysa in older patients?

Official prescribing information does not require a special dose adjustment based on age alone. However, factors common in older individuals, such as low body weight or impaired kidney function, are criteria that may trigger a mandatory dose reduction. Older patients may also have an inherently higher general risk of bleeding.

Q: Do I need to carry a special alert card when taking Savaysa?

Official patient information indicates that individuals taking Savaysa are advised to carry a patient alert card at all times. This is intended to inform any healthcare professional, including surgeons or dentists, that the individual is currently taking a blood thinner.

Q: Can taking Savaysa lead to hair loss or changes in weight?

Based on the main clinical trial data submitted to regulatory agencies, hair loss or changes in weight are not listed among the common or frequent side effects of edoxaban.

Q: Is fatigue a known side effect of Savaysa?

Yes, the official list of known adverse reactions for edoxaban includes the potential for unusual tiredness or weakness. If this or any other potential side effect is experienced, further guidance should be sought from a healthcare professional.

Q: What should I do if I notice unusual bleeding while on Savaysa?

Official guidance states that if severe or uncontrolled bleeding is experienced—such as vomiting or coughing up blood—emergency medical attention should be sought immediately. It is also important to contact a healthcare professional regarding any new or concerning bleeding event.

Q: If I need emergency surgery, can the effects of Savaysa be reversed?

Regulatory safety information states that there is no established method to reliably reverse the blood-thinning effects of Savaysa. The effects of the last dose are generally expected to persist for approximately 24 hours, meaning the risk of bleeding is increased if surgery cannot be delayed.

Q: What is the name of the reversal agent for Savaysa?

Official prescribing information states there is no FDA-approved specific reversal agent available for the anticoagulant effects of Savaysa.

Q: How long is a typical treatment period with Savaysa?

The total duration of therapy is a decision made by a healthcare provider based on the condition being treated. Studies for deep vein thrombosis (DVT) typically involve treatment periods of 3 to 12 months. However, for stroke prevention in atrial fibrillation, treatment is often intended to be long-term.

Q: What happens if I take too much Savaysa by accident?

Taking more than the prescribed dose significantly increases the risk of uncontrolled bleeding. Symptoms of overdose may include bloody stools or urine, or unusual bruising. Official guidance states that emergency medical attention must be sought immediately if an overdose is suspected.

Q: Will Savaysa affect my ability to drive or operate machinery?

Official regulatory information indicates that Savaysa has no or negligible influence on the ability to drive or use machines. However, if side effects such as dizziness or fatigue are experienced, caution is recommended when performing such tasks.

Q: Are there any specific foods that interfere with Savaysa?

No, official product information confirms that there are no special dietary restrictions needed when taking Savaysa. Unlike some older blood thinners, a normal diet can be maintained.

Q: Does Savaysa have any effect on menstrual bleeding?

As a blood thinner, Savaysa can potentially cause or increase the severity of heavy non-menstrual vaginal bleeding or other forms of bleeding. If unusual bleeding that is heavier than normal is experienced, a healthcare professional should be contacted.

Q: Does Savaysa impact fertility?

Official product information and clinical data suggest there is no evidence that taking edoxaban (Savaysa) affects fertility in either men or women.

Q: Is it normal to feel dizzy when first starting Savaysa?

Dizziness is listed as a potential side effect of edoxaban in regulatory adverse reactions data. If dizziness is experienced, further guidance should be sought from a healthcare professional.

Q: Can Savaysa interact with herbal remedies like St. John's Wort?

Regulatory warnings indicate that the herbal remedy St. John’s Wort must not be taken concurrently with Savaysa, as it can significantly decrease the effectiveness of the medication. It is important that all herbal remedies and supplements are disclosed to a healthcare professional.

Q: Does Savaysa cause any stomach issues like nausea or heartburn?

Yes, official adverse reaction data for edoxaban lists nausea (feeling sick) and dyspepsia (commonly known as heartburn) as known potential side effects.

Q: Is it safe to get dental work done while taking Savaysa?

It is important for patients to always inform their dentist that they are taking Savaysa. For minor procedures, interruption of the medicine may not be necessary. For more invasive dental procedures, a protocol involving temporarily holding the dose may be followed, as determined by the healthcare team.

Q: How does Savaysa work differently from aspirin?

Savaysa is an anticoagulant that targets a specific protein, Factor Xa, in the blood clotting cascade. In contrast, aspirin is an antiplatelet agent that works by limiting the ability of platelets to aggregate together. Regulatory warnings state that taking both medicines together increases the risk of bleeding.

Q: Is the long-term use of Savaysa generally considered safe?

Clinical trials established the efficacy and safety of Savaysa for continuous, long-term use for stroke prevention in nonvalvular atrial fibrillation. These studies showed that it was associated with a significantly lower rate of major bleeding when compared to warfarin.

Q: Can I take Savaysa if I am already taking medication for high blood pressure?

Most common blood pressure medicines do not have a specific drug-drug interaction with Savaysa. However, regulatory documents warn that some calcium channel blockers, such as Diltiazem or Verapamil, may increase Savaysa levels, which could require a dose reduction. It is important that all current medications are discussed with a healthcare professional.

Q: Does Savaysa affect cholesterol levels?

According to the clinical trial data submitted for regulatory approval, changes in cholesterol levels are not listed among the common or frequent side effects of edoxaban.

How should Savaysa be stored and disposed of?

How to Store and Dispose of Savaysa?

Savaysa (edoxaban) must be stored and handled according to specific regulatory requirements to maintain its stability and ensure safety.


Official Storage Conditions

Savaysa tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The medication should be kept in its original container with the cap tightly closed and stored away from direct light, excess heat, and moisture.


Protection and Disposal

Mandatory safety rules require that Savaysa must be kept out of the sight and reach of children at all times. Disposal of any unused or expired tablets and the container must be carried out according to local regulations. The active substance is noted as persistent in the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Savaysa found in:

A-Z Index: